- Home
- ICON vs ALLR Comparison
ICON vs ALLR Comparison
Compare ICON & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- ALLR
- Stock Information
- Founded
- ICON 2023
- ALLR 2004
- Country
- ICON Greece
- ALLR United States
- Employees
- ICON N/A
- ALLR N/A
- Industry
- ICON
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- ALLR Health Care
- Exchange
- ICON Nasdaq
- ALLR Nasdaq
- Market Cap
- ICON 4.7M
- ALLR 4.6M
- IPO Year
- ICON 2024
- ALLR N/A
- Fundamental
- Price
- ICON $2.06
- ALLR $1.01
- Analyst Decision
- ICON Strong Buy
- ALLR
- Analyst Count
- ICON 1
- ALLR 0
- Target Price
- ICON $7.00
- ALLR N/A
- AVG Volume (30 Days)
- ICON 58.1K
- ALLR 441.9K
- Earning Date
- ICON 02-15-2025
- ALLR 11-14-2024
- Dividend Yield
- ICON 3.98%
- ALLR N/A
- EPS Growth
- ICON N/A
- ALLR N/A
- EPS
- ICON 0.35
- ALLR N/A
- Revenue
- ICON $4,810,000.00
- ALLR N/A
- Revenue This Year
- ICON $41.29
- ALLR N/A
- Revenue Next Year
- ICON $130.65
- ALLR N/A
- P/E Ratio
- ICON $5.80
- ALLR N/A
- Revenue Growth
- ICON 5.71
- ALLR N/A
- 52 Week Low
- ICON $1.81
- ALLR $0.90
- 52 Week High
- ICON $3.85
- ALLR $348.00
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- ALLR 38.58
- Support Level
- ICON N/A
- ALLR $0.91
- Resistance Level
- ICON N/A
- ALLR $1.34
- Average True Range (ATR)
- ICON 0.00
- ALLR 0.11
- MACD
- ICON 0.00
- ALLR 0.02
- Stochastic Oscillator
- ICON 0.00
- ALLR 21.61
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.